Fig. 5.

Axitinib abrogates nitric oxide synthase 2 (NOS2)-mediated nitric oxide production. A: cells recovered from BAL fluid of control mice and mice with Tsc2-null lesions treated with diluent or axitinib were analyzed for Nos2 mRNA expression by quantitative RT-PCR and normalized to β-actin. Values are fold change (means ± SE, n = 3–5 per each group). B: BAL fluid was collected at 21 days post-TMKOC cell injection and analyzed for nitric oxide metabolites by chemical reduction, as described in materials and methods. Values are means ± SE (control/diluent, n = 5; control/axitinib, n = 5; Tcs2-null/diluent, n = 15; Tsc2/axinitib, n = 10). P < 0.05 vs. *control/diluent group and #Tsc2-null/diluent group by two-way ANOVA and Bonferroni correction for multiple comparisons.